- Angry questions in Germany after Christmas market attack
- China's Zheng pulls out of season-opening United Cup
- Minorities fear targeted attacks in post-revolution Bangladesh
- Tatum's 43-point triple-double propels Celtics over Bulls
- Tunisia women herb harvesters struggle with drought and heat
- Trump threatens to take back control of Panama Canal
- India's architecture fans guard Mumbai's Art Deco past
- Secretive game developer codes hit 'Balatro' in Canadian prairie province
- Large earthquake hits battered Vanuatu
- Beaten Fury says Usyk got 'Christmas gift' from judges
- First Singaporean golfer at Masters hopes 'not be in awe' of heroes
- Usyk beats Fury in heavyweight championship rematch
- Stellantis backtracks on plan to lay off 1,100 at US Jeep plant
- Atletico snatch late win at Barca to top La Liga
- Australian teen Konstas ready for Indian pace challenge
- Strong quake strikes off battered Vanuatu
- Tiger Woods and son Charlie share halfway lead in family event
- Bath stay out in front in Premiership as Bristol secure record win
- Mahomes shines as NFL-best Chiefs beat Texans to reach 14-1
- Suspect in deadly Christmas market attack railed against Islam, Germany
- MLB legend Henderson, career stolen base leader, dead at 65
- Albania announces shutdown of TikTok for at least a year
- Laboured Napoli take top spot in Serie A
- Schick hits four as Leverkusen close gap to Bayern on sombre weekend
- Calls for more safety measures after Croatia school stabbings
- Jesus double lifts Christmas spirits for five-star Arsenal
- Frankfurt miss chance to close on Bayern as attack victims remembered
- NBA fines Celtics coach Mazzulla and Nets center Claxton
- Banned Russian skater Valieva stars at Moscow ice gala
- Leading try scorer Maqala takes Bayonne past Vannes in Top 14
- Struggling Southampton appoint Juric as new manager
- Villa heap pain on slumping Man City as Forest soar
- Suspect in deadly Christmas market attack railed against Islam and Germany
- At least 32 die in bus accident in southeastern Brazil
- Freed activist Paul Watson vows to 'end whaling worldwide'
- Chinese ship linked to severed Baltic Sea cables sets sail
- Sorrow and fury in German town after Christmas market attack
- Guardiola vows Man City will regain confidence 'sooner or later' after another defeat
- Ukraine drone hits Russian high-rise 1,000km from frontline
- Villa beat Man City to deepen Guardiola's pain
- 'Perfect start' for ski great Vonn on World Cup return
- Germany mourns five killed, hundreds wounded in Christmas market attack
- Odermatt soars to Val Gardena downhill win
- Mbappe's adaptation period over: Real Madrid's Ancelotti
- France's most powerful nuclear reactor finally comes on stream
- Ski great Vonn finishes 14th on World Cup return
- Scholz visits site of deadly Christmas market attack
- Heavyweight foes Usyk, Fury set for titanic rematch
- Drone attack hits Russian city 1,000km from Ukraine frontier
- Former England winger Eastham dies aged 88
Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
Nogueira--PC